Evaluation of multimeric tyrosine-o-sulfate as a cytoprotectant in an in vivo model of acute myocardial infarction in pigs

Cardiology

Volumn 121, Issue 1, 2012, Pages 59-70

  Banz, Yara ^a   Hess, Otto M ^b   Meier, Pascal ^b   Korchagina, Elena Y ^c   Gordeeva, Elena A ^c   Robson, Simon C ^d   Gajanayake, Thusitha ^a   Csizmadia, Eva ^d   Mettler, Daniel ^a   Haeberli, Andr ^a   Bovin, Nicolai V ^c   Rieben, Robert ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b BERN UNIVERSITY HOSPITAL   (Switzerland)

^c SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^d HARVARD UNIVERSITY   (United States)

Author keywords

Coagulation; Complement; Ischemia reperfusion injury; Multimeric tyrosine sulfate; Myocardial infarction

Indexed keywords

CREATINE KINASE; PHOSPHATE BUFFERED SALINE; THROMBOPLASTIN; TYROSINE SULFATE;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BALLOON OCCLUSION; BLOOD CLOTTING; CELL PROTECTION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG BINDING; EXPERIMENTAL PIG; EXTRAVASATION; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HISTOPATHOLOGY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; ANTICOAGULANTS; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT PATHWAY, CLASSICAL; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; GRANULOCYTES; HEMODYNAMICS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; NEUTROPHILS; SUS SCROFA; THROMBOPLASTIN; TYROSINE; VENTRICULAR FIBRILLATION;

EID: 84857713708     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000336485     Document Type: Article

References (43)

1. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT: Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing postischemic myocardial inflammation and necrosis. Science 1990; 249: 146-151.
2. Golino P, Ragni M, Cirillo P, Avvedimento VE, Feliciello A, Esposito N, Scognamiglio A, Trimarco B, Iaccarino G, Condorelli M, Chiariello M, Ambrosio G: Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med 1996; 2: 35-40. (Pubitemid 26028070)
3. Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL: Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182: 1807-1814.
4. Koo DD, Welsh KI, Roake JA, Morris PJ, Fuggle SV: Ischemia/reperfusion injury in human kidney transplantation: An immunohistochemical analysis of changes after reperfusion. Am J Pathol 1998; 153: 557-566. (Pubitemid 28373666)
5. Erlich JH, Boyle EM, Labriola J, Kovacich JC, Santucci RA, Fearns C, Morgan EN, Yun W, Luther T, Kojikawa O, Martin TR, Pohlman TH, Verrier ED, Mackman N: Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol 2000; 157: 1849-1862.
6. Pochechueva TV, Ushakova NA, Preobrazhenskaya ME, Nifantiev NE, Tsvetkov YE, Sablina MA, Tuzikov AB, Bird MI, Rieben R, Bovin NV: P-selectin blocking potency of multimeric tyrosine sulfates in vitro and in vivo. Bioorg Med Chem Lett 2003; 13: 1709-1712. (Pubitemid 36561147)
7. Laumonier T, Walpen AJ, Matozan KM, Korchagina EY, Bovin NV, Haeberli A, Mohacsi PJ, Rieben R: Multimeric tyrosine sulfate acts as an endothelial cell protectant and prevents complement activation in xenotransplantation models. Xenotransplantation 2004; 11: 262-268. (Pubitemid 38623063)
8. Banz Y, Hess OM, Robson SC, Mettler D, Meier P, Haeberli A, Csizmadia E, Korchagina EY, Bovin NV, Rieben R: Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischaemia/ reperfusion injury. Eur Heart J 2005; 26: 2334-2343. (Pubitemid 41541401)
9. Meri S, Pangburn MK: Regulation of alternative pathway complement activation by glycosaminoglycans: Specificity of the polyanion binding site on factor H. Biochem Biophys Res Commun 1994; 198: 52-59. (Pubitemid 24172719)
10. Wuillemin WA, te Velthuis H, Lubbers YT, de Ruig CP, Eldering E, Hack CE: Potentiation of C1 inhibitor by glycosaminoglycans: Dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J Immunol 1997; 159: 1953-1960. (Pubitemid 127484185)
11. Laumonier T, Walpen A, Maurus C, Mohacsi PJ, Matozan K, Korchagina E, Bovin N, Vanhove B, Seebach JD, Rieben R: Dextran sulfate acts as an endothelial cell protectant and inhibits human complement- and NK cell-mediated cytotoxicity against porcine cells. Transplantation 2003; 76: 838-843. (Pubitemid 37142458)
12. Bourin MC, Lindahl U: Glycosaminoglycans and the regulation of blood coagulation. Biochem J 1993; 289: 313-330. (Pubitemid 23042035)
13. Mauron T, Lammle B, Wuillemin WA: Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins. Thromb Haemost 1998; 80: 82-86. (Pubitemid 28353503)
14. Zeerleder S, Mauron T, Lammle B, Wuillemin WA: Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests. Thromb Res 2002; 105: 441-446. (Pubitemid 34621262)
15. Bovin NV, Korchagina E, Zemlyanukhina TV, Byramova NE, Galanina OE, Zemlyakov AE, IVanov AE, Zubov VP, Mochalova LV: Synthesis of polymeric neoglycoconjugates based on N-substituted polyacrylamides. Glycoconj J 1993; 10: 142-151. (Pubitemid 23233227)
16. Gordeeva EA, Tuzikov AB, Galanina OE, Pochechueva TV, Bovin NV: Microscale synthesis of glycoconjugate series and libraries. Anal Biochem 2000; 278: 230-232. (Pubitemid 30090748)
17. Daha MR, Van Es LA: Enhanced alternative complement pathway-dependent degradation of soluble immunoglobulin aggregates by macrophages. Immunology 1981; 43: 513-518. (Pubitemid 11095782)
18. Banz Y, Hess OM, Robson SC, Csizmadia E, Mettler D, Meier P, Haeberli A, Shaw S, Smith RA, Rieben R: Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1. Cardiovasc Res 2007; 76: 482-493. (Pubitemid 350007457)
19. Klein HH, Puschmann S, Schaper J, Schaper W: The mechanisms of the tetrazolium reaction in identifying experimental myocardial infarction. Virchows Arch 1981; 393: 287-297. (Pubitemid 11031537)
20. Dodge HT, Sandler H, Ballew DW, Lord JD Jr: The use of biplane angiocardiography for the measurement of left ventricular volume in man. Am Heart J 1960; 60: 762-776.
21. Pratt JR, Jones ME, Dong J, Zhou W, Chowdhury P, Smith RA, Sacks SH: Nontransgenic hyperexpression of a complement regulator in donor kidney modulates transplant ischemia/reperfusion damage, acute rejection, and chronic nephropathy. Am J Pathol 2003; 163: 1457-1465. (Pubitemid 37175093)
22. Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT: In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigeninlabeled factors VIIa and X. Lab Invest 1996; 75: 451-461. (Pubitemid 26346797)
23. Gollackner B, Goh SK, Qawi I, Buhler L, Knosalla C, Daniel S, Kaczmarek E, Awwad M, Cooper DK, Robson SC: Acute vascular rejection of xenografts: Roles of natural and elicited xenoreactive antibodies in activation of vascular endothelial cells and induction of procoagulant activity. Transplantation 2004; 77: 1735-1741. (Pubitemid 38780542)
24. Homeister JW, Satoh P, Lucchesi BR: Effects of complement activation in the isolated heart. Role of the terminal complement components. Circ Res 1992; 71: 303-319.
25. Tanhehco EJ, Yasojima K, McGeer PL, McGeer EG, Lucchesi BR: Preconditioning reduces myocardial complement gene expression in vivo. Am J Physiol Heart Circ Physiol 2000; 279:H1157-H1165.
26. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R: Postconditioning and protection from reperfusion injury: Where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2010; 87: 406-423.
27. Rodriguez-Sinovas A, Cabestrero A, Garcia del Blanco B, Inserte J, Garcia A, Garcia-Dorado D: Intracoronary acid infusion as an alternative to ischemic postconditioning in pigs. Basic Res Cardiol 2009; 104: 761-771.
28. Brener SJ, Topol EJ: Adjunctive therapy for percutaneous revascularization in acute myocardial infarction. Curr Pharm Des 2004; 10: 399-405. (Pubitemid 38159870)
29. Mizutani A, Okajima K, Uchiba M, Isobe H, Harada N, Mizutani S, Noguchi T: Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003; 101: 3029-3036. (Pubitemid 36857991)
30. Thourani VH, Brar SS, Kennedy TP, Thornton LR, Watts JA, Ronson RS, Zhao ZQ, Sturrock AL, Hoidal JR, Vinten-Johansen J: Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2000; 278:H2084-H2093. (Pubitemid 30439223)
31. Lauver DA, Booth EA, White AJ, Poradosu E, Lucchesi BR: Sulodexide (KRX-101) attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis. J Pharmacol Exp Ther 2004; 312: 794-800. (Pubitemid 40189581)
32. Black SC, Gralinski MR, Friedrichs GS, Kilgore KS, Driscoll EM, Lucchesi BR: Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res 1995; 29: 629-636.
33. Mitroulis I, Kambas K, Anyfanti P, Doumas M, Ritis K: The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention. Expert Opin Ther Targets 2011; 15: 75-89.
34. Sevastos J, Kennedy SE, Davis DR, Sam M, Peake PW, Charlesworth JA, Mackman N, Erlich JH: Tissue factor deficiency and PAR- 1 deficiency are protective against renal ischemia reperfusion injury. Blood 2007; 109: 577-583. (Pubitemid 46105956)
35. Ma XL, Tsao PS, Viehman GE, Lefer AM: Neutrophil-mediated vasoconstriction and endothelial dysfunction in low-flow perfusion- reperfused cat coronary artery. Circ Res 1991; 69: 95-106.
36. Kloner RA, Ganote CE, Jennings RB: The 'no-reflow' phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54: 1496-1508.
37. Ito WD, Schaarschmidt S, Klask R, Hansen S, Schafer HJ, Mathey D, Bhakdi S: Infarct size measurement by triphenyltetrazolium chloride staining versus in vivo injection of propidium iodide. J Mol Cell Cardiol 1997; 29: 2169-2175. (Pubitemid 27348527)
38. Schaper W, Frenzel H, Hort W: Experimental coronary artery occlusion. I. Measurement of infarct size. Basic Res Cardiol 1979; 74: 46-53. (Pubitemid 9183394)
39. Zmudka K, Dubiel J, Vanhaecke J, Flameng W, De Geest H: Effects of oral pretreatment with metoprolol on left ventricular wall motion, infarct size, hemodynamics, and regional myocardial blood flow in anesthetized dogs during thrombotic coronary artery occlusion and reperfusion. Cardiovasc Drugs Ther 1994; 8: 479-487. (Pubitemid 24239715)
40. Horstick G, Berg O, Heimann A, Gotze O, Loos M, Hafner G, Bierbach B, Petersen S, Bhakdi S, Darius H, Horstick M, Meyer J, Kempski O: Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: Dose-related beneficial versus detrimental effects. Circulation 2001; 104: 3125-3131. (Pubitemid 34014069)
41. Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW: Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108: 1184-1190. (Pubitemid 37099985)
42. Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, Hochman JS, Filloon TG, Mojcik CF, Todaro TG, Armstrong PW: Effect of pexelizumab, an anti- C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003; 108: 1176-1183. (Pubitemid 37099984)
43. Hausenloy DJ, Baxter G, Bell R, Botker HE, Davidson SM, Downey J, Heusch G, Kitakaze M, Lecour S, Mentzer R, Mocanu MM, Ovize M, Schulz R, Shannon R, Walker M, Walkinshaw G, Yellon DM: Translating novel strategies for cardioprotection: The Hatter Workshop Recommendations. Basic Res Cardiol 2010; 105: 677-686.